Literature DB >> 18727801

Activities of antistaphylococcal antibiotics towards the extracellular and intraphagocytic forms of Staphylococcus aureus isolates from a patient with persistent bacteraemia and endocarditis.

S Lemaire1, K Kosowska-Shick, K Julian, P M Tulkens, F Van Bambeke, P C Appelbaum.   

Abstract

Decreased susceptibility of Staphylococcus aureus to antistaphylococcal agents may be associated with inability to eradicate intracellular forms, which could explain therapeutic failures. This hypothesis was tested using clinical isolates obtained from a patient with persistent staphylococcal bacteraemia under therapy. Four isogenic isolates (three from tissue, one from blood) with increased MICs for vancomycin (1-4 mg/L) and for daptomycin (1-4 mg/L) were collected after an initial 16-day treatment with vancomycin-rifampicin-gentamicin, followed by 13-20 days of treatment with daptomycin-rifampicin-gentamicin. Isolates were tested for MICs and for: (i) vancomycin (BODIPY-FL-vancomycin) and daptomycin binding; (ii) cell wall turnover (loss of N-acetyl-d-[1-(14)C]glucosamine in 30 min after 1 h of labelling); and (iii) Triton X-100-induced autolysis. Extracellular (broth) and intracellular (THP-1 macrophages) activities of rifampicin, linezolid and fusidic acid at C(max), and of vancomycin, daptomycin, quinupristin-dalfopristin and oritavancin over a wide range of extracellular concentrations (with pharmacological modelling to determine E(max)), were measured at 24 h. Increases in vancomycin MICs correlated with increased drug binding, and decreased cell wall turnover and detergent-induced autolysis. Increases in daptomycin MICs correlated with decreased daptomycin binding. Intracellular activity was weak (E(max) <1 log(10) CFU decrease) for vancomycin against all isolates, and for daptomycin against isolates with MICs >1 mg/L. Among all antibiotics tested, only quinupristin-dalfopristin and oritavancin provided close to bactericidal intracellular activities (1.6-2.5 log(10) CFU decreases at C(max)). Determination of the intracellular susceptibility of S. aureus, combined with improved methods of diagnosis, could be useful when dealing with persistent staphylococcal infections and could improve therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18727801     DOI: 10.1111/j.1469-0691.2008.02035.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  15 in total

1.  Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.

Authors:  Sandrine Lemaire; Klaudia Kosowska-Shick; Peter C Appelbaum; Gunther Verween; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2010-04-12       Impact factor: 5.191

2.  Study of macrophage functions in murine J774 cells and human activated THP-1 cells exposed to oritavancin, a lipoglycopeptide with high cellular accumulation.

Authors:  Sandrine Lemaire; Marie-Paule Mingeot-Leclercq; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2014-01-21       Impact factor: 5.191

Review 3.  New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.

Authors:  George G Zhanel; Divna Calic; Frank Schweizer; Sheryl Zelenitsky; Heather Adam; Philippe R S Lagacé-Wiens; Ethan Rubinstein; Alfred S Gin; Daryl J Hoban; James A Karlowsky
Journal:  Drugs       Date:  2010-05-07       Impact factor: 9.546

4.  Reduced vancomycin susceptibility in an in vitro catheter-related biofilm model correlates with poor therapeutic outcomes in experimental endocarditis due to methicillin-resistant Staphylococcus aureus.

Authors:  Wessam Abdelhady; Arnold S Bayer; Kati Seidl; Cynthia C Nast; Megan R Kiedrowski; Alexander R Horswill; Michael R Yeaman; Yan Q Xiong
Journal:  Antimicrob Agents Chemother       Date:  2013-01-07       Impact factor: 5.191

5.  Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus.

Authors:  Sandrine Lemaire; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2010-12-06       Impact factor: 5.191

6.  Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial.

Authors:  Lala M Dunbar; Joe Milata; Ty McClure; Margaret M Wasilewski
Journal:  Antimicrob Agents Chemother       Date:  2011-05-02       Impact factor: 5.191

7.  Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis.

Authors:  H F Chambers; L Basuino; B A Diep; J Steenbergen; S Zhang; P Tattevin; J Alder
Journal:  Antimicrob Agents Chemother       Date:  2009-01-26       Impact factor: 5.191

8.  Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype and revertant strains.

Authors:  Hoang Anh Nguyen; Olivier Denis; Anne Vergison; Anne Theunis; Paul M Tulkens; Marc J Struelens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

9.  Intracellular persisting Staphylococcus aureus is the major pathogen in recurrent tonsillitis.

Authors:  Andreas E Zautner; Merit Krause; Gerhard Stropahl; Silva Holtfreter; Hagen Frickmann; Claudia Maletzki; Bernd Kreikemeyer; Hans Wilhelm Pau; Andreas Podbielski
Journal:  PLoS One       Date:  2010-03-01       Impact factor: 3.240

10.  Combination therapy with iron chelation and vancomycin in treating murine staphylococcemia.

Authors:  G Luo; B Spellberg; T Gebremariam; H Lee; Y Q Xiong; S W French; A Bayer; A S Ibrahim
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-12-01       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.